Liver cancer drug combo study halted early
NCT ID NCT05220722
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 28 times
Summary
This study tested a new drug called SD-101, given directly into the liver's blood supply, along with standard immunotherapy drugs, for people with two types of liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma). The goal was to find a safe dose and see if the combination could shrink tumors. The study was stopped early after enrolling 23 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.